Literature DB >> 8961172

In-vivo clearance study of vancomycin in rats.

T Nakamura1, M Takano, M Yasuhara, K Inui.   

Abstract

The renal handling of vancomycin in rats and the effects of various drugs (probenecid, cimetidine and quinidine) on urinary excretion of the antibiotic were investigated by in-vivo clearance. The vancomycin-to-inulin excretion ratio (ER) was greater than unity at various infusion rates of vancomycin. Quinidine, co-administered with vancomycin, significantly decreased the total, renal and net secretory clearance of the antibiotic. Cimetidine also decreased, though not significantly, the secretory clearance of vancomycin by about 20%, but probenecid did not. These results suggested that vancomycin is secreted in renal tubules in rats, and that quinidine decreases the total clearance of vancomycin partly by inhibiting its tubular secretion in the kidney.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8961172     DOI: 10.1111/j.2042-7158.1996.tb03920.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  11 in total

1.  Formulation and evaluation of a folic acid receptor-targeted oral vancomycin liposomal dosage form.

Authors:  K E Anderson; L A Eliot; B R Stevenson; J A Rogers
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

2.  PEGylated liposome encapsulation increases the lung tissue concentration of vancomycin.

Authors:  Krishna Muppidi; Jeffrey Wang; Guru Betageri; Andrew S Pumerantz
Journal:  Antimicrob Agents Chemother       Date:  2011-07-25       Impact factor: 5.191

3.  Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats.

Authors:  T Nakamura; Y Hashimoto; T Kokuryo; K I Inui
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

4.  Immunocytochemistry for vancomycin using a monoclonal antibody that reveals accumulation of the drug in rat kidney and liver.

Authors:  Kunio Fujiwara; Yohei Yoshizaki; Masashi Shin; Tsubasa Miyazaki; Tetsuya Saita; Shuichi Nagata
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

Review 5.  Vancomycin-Induced Kidney Injury: Animal Models of Toxicodynamics, Mechanisms of Injury, Human Translation, and Potential Strategies for Prevention.

Authors:  Gwendolyn M Pais; Jiajun Liu; Sanja Zepcan; Sean N Avedissian; Nathaniel J Rhodes; Kevin J Downes; Ganesh S Moorthy; Marc H Scheetz
Journal:  Pharmacotherapy       Date:  2020-05-04       Impact factor: 4.705

6.  Megalin Blockade with Cilastatin Suppresses Drug-Induced Nephrotoxicity.

Authors:  Yoshihisa Hori; Nobumasa Aoki; Shoji Kuwahara; Michihiro Hosojima; Ryohei Kaseda; Sawako Goto; Tomomichi Iida; Shankhajit De; Hideyuki Kabasawa; Reika Kaneko; Hiroyuki Aoki; Yoshinari Tanabe; Hiroshi Kagamu; Ichiei Narita; Toshiaki Kikuchi; Akihiko Saito
Journal:  J Am Soc Nephrol       Date:  2017-01-04       Impact factor: 10.121

7.  Development and stability studies of novel liposomal vancomycin formulations.

Authors:  Krishna Muppidi; Andrew S Pumerantz; Jeffrey Wang; Guru Betageri
Journal:  ISRN Pharm       Date:  2012-01-26

8.  Intestinal and hepatic expression of cytochrome P450s and mdr1a in rats with indomethacin-induced small intestinal ulcers.

Authors:  Shoji Kawauchi; Tsutomu Nakamura; Hiroyuki Yasui; Chikako Nishikawa; Ikuya Miki; Jun Inoue; Sayo Horibe; Tsuneo Hamaguchi; Toshihito Tanahashi; Shigeto Mizuno
Journal:  Int J Med Sci       Date:  2014-09-13       Impact factor: 3.738

9.  Exposure to Hyperbaric Oxygen Intensified Vancomycin-Induced Nephrotoxicity in Rats.

Authors:  Itay M Sabler; Matitiahu Berkovitch; Judith Sandbank; Eran Kozer; Zahi Dagan; Michael Goldman; Hilla Bahat; Kobi Stav; Amnon Zisman; Baruch Klin; Ibrahim Abu-Kishk
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240

10.  Protective Effects of Cilastatin against Vancomycin-Induced Nephrotoxicity.

Authors:  Blanca Humanes; Juan Carlos Jado; Sonia Camaño; Virginia López-Parra; Ana María Torres; Luís Antonio Álvarez-Sala; Emilia Cercenado; Alberto Tejedor; Alberto Lázaro
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.